



Balfour Capital Group Incyte Corporation

Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware. Founded in 2002, it focuses on discovering, developing, and commercializing proprietary therapeutics in oncology, inflammation, and autoimmunity. The company has a diverse portfolio, including nine approved products and ongoing clinical trials in various disease areas. Incyte operates with over 2,500 employees across North America, Europe, and Asia.

1. Top 5 Competitors

Incyte operates in a competitive biopharmaceutical landscape. Its top competitors include:

- Alnylam Pharmaceuticals (ALNY)
- Biogen (BIIB)
- United Therapeutics (UTHR)
- Exelixis (EXEL)
- Neurocrine Biosciences (NBIX)

These companies are prominent in the biotechnology industry, focusing on areas overlapping with Incyte's therapeutic targets.

2. Largest Institutional Shareholders

As of the latest filings, Incyte's largest institutional shareholders are:

- Baker Bros. Advisors LP: 15.88% ownership
- Vanguard Fiduciary Trust Co.: 10.33%
- Dodge & Cox: 7.68%
- BlackRock Advisors LLC: 7.20%
- State Street Corp.: 5.19%

Collectively, institutional investors own approximately 96.97% of Incyte's outstanding shares.

3. Management Team

Incyte's leadership comprises experienced professionals:

- Hervé Hoppenot: Chairman, President, and CEO
- Pablo J. Cagnoni, M.D.: President, Head of Research & Development
- Christiana Stamoulis, MBA: Executive Vice President and Chief Financial Officer
- Vijay Iyengar, M.D.: Executive Vice President, Head of Global Medical Affairs, Product and Partnership Strategy
- Lee Heeson: Executive Vice President, Head of Incyte International
- Michael Morrissey: Executive Vice President, Head of Global Technical Operation.



Balfour Capital Group Incyte Corporation

4. Revenue

Incyte reported total revenues of \$4.2 billion for the full year 2024, marking a 15% increase year-over-year.

5. Institutions with Buy Recommendations:

Several financial institutions have recently issued buy recommendations for Incyte:

- Jefferies: Initiated coverage with a Buy rating on February 23, 2024.
- Citigroup: Initiated coverage with a Buy rating on July 25, 2023.

6. Analyst Sentiment Summary

Analyst sentiment towards Incyte is moderately positive:

- Average Recommendation: Overweight
- Average Target Price: \$73.95
- Number of Ratings: 29
- Buy Percentage Consensus: Approximately 74% of analysts recommend a Buy.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, Incyte insiders have sold a total of 113,021 shares, amounting to approximately \$7.66 million. Notable insider sales include:

- Barry P. Flannelly: \$3.36 million
- Vijay K. Iyengar: \$1.59 million
- Sheila A. Denton: \$1.08 million

There have been no reported insider purchases during this period.